Trials / Completed
CompletedNCT01908322
Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
SORINT - SORafenib for Treatment of Patients With INTermediate Stage Hepatocellular Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 19 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The study aims to investigate patient characteristics of intermediate stage hepatocellular carcinoma patients treated with Nexavar and their distribution to different treatment groups as well as determining efficacy and safety parameters.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2015-06-01
- Completion
- 2015-09-01
- First posted
- 2013-07-25
- Last updated
- 2015-11-11
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01908322. Inclusion in this directory is not an endorsement.